Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) shares saw an uptick in trading volume on Thursday . 57,734 shares changed hands during trading, a decline of 1% from the previous session’s volume of 58,351 shares.The stock last traded at $55.5750 and had previously closed at $52.04.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on NBTX shares. UBS Group boosted their price target on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. TD Cowen restated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Finally, Guggenheim lifted their price objective on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $26.67.
Check Out Our Latest Stock Analysis on Nanobiotix
Nanobiotix Stock Up 5.5%
Nanobiotix (NASDAQ:NBTX – Get Free Report) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $3.42 million during the quarter. On average, equities research analysts predict that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.
Institutional Trading of Nanobiotix
Several institutional investors and hedge funds have recently modified their holdings of NBTX. Optiver Holding B.V. bought a new stake in shares of Nanobiotix during the 3rd quarter worth $101,000. Marshall Wace LLP bought a new position in Nanobiotix in the fourth quarter valued at about $220,000. Royal Bank of Canada raised its position in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix in the fourth quarter valued at about $390,000. 38.81% of the stock is currently owned by institutional investors.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.
Featured Stories
- Five stocks we like better than Nanobiotix
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
- The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector Gains
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
